Our multidisciplinary approach to clinical care has made the Icahn School of Medicine at Mount Sinai a magnet for those seeking personalized treatment for hepatitis B and C virus infections, autoimmune and drug-induced liver disease, hepatic fibrosis, steatotic liver disease (previously known as fatty liver disease), cirrhosis, and liver cancer. By closely collaborating with specialists in transplantation, pathology, radiology, and oncology, we deliver integrative plans that are tailored to each patient's needs. Within the Mount Sinai Health System, we offer advanced treatment at four sites: The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, and Mount Sinai-Union Square.

Additionally, the Institute for Liver Research at the Icahn School of Medicine at Mount Sinai is a multidisciplinary program dedicated to advancing basic and translational research in liver biology and disease. It focuses on identifying therapeutic targets and developing novel treatments for conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, liver fibrosis, and liver cancer, leveraging Mount Sinai's strengths in genomics, immunology, and more.

We remain equally dedicated to training the next generation of premier hepatologists. The Division’s Transplant Hepatology Fellowship at The Mount Sinai Hospital offers advanced clinical training to applicants who have also completed a gastroenterology fellowship. This program was the first of its kind to be approved by the Accreditation Council for Graduate Medical Education (ACGME) in the Northeast and remains one of the largest such fellowships in the United States.